Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1699998 | 0.89 | SLC6A12 (0.31) | SLC6A12SLC6A11 | |
| SCHEMBL28109336 | 0.79 | OPRL1 (0.30) | — | |
| Trifluoroacetic Acid SCHEMBL3025153 | 0.79 | OAT (0.36) | — | |
| Trifluoroacetic Acid SCHEMBL22191335 | 0.79 | ALDH1A1 (0.39) | — | |
| Trifluoroacetic Acid SCHEMBL15751671 | 0.79 | FFAR4 (0.33) | — | |
| SCHEMBL2931534 | 0.77 | — | — | |
| Trifluoroacetic Acid SCHEMBL28133460 | 0.77 | OAT (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL3154232 | 0.77 | OAT (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL7946360 | 0.76 | HSD11B1 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL21403913 | 0.76 | HSD11B1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SLC6A12 4784/4885SLC6A11 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.